supp.fit

Butyrate: study protocols

32 study groups say how much Butyrate participants took a day. These are the doses the studies gave. They are not a recommendation.

Butyrate: what the research found →

Dose per serving from products

25 products in our catalogue print how much Butyrate a serving holds.

Most common: 100 mg to 250 mg, 32% of 25 products.

Dose per servingProducts
25 mg to 50 mg
3
50 mg to 100 mg
0
100 mg to 250 mg
8
250 mg to 500 mg
2
500 mg to 1 g
6
1 g to 2.5 g
6

Dose per serving from research

26 study groups in 23 studies say how much Butyrate participants took a day.

These are the doses the studies gave. They are not a recommendation.

Most common: 500 mg to 1 g, 38% of 26 study groups.

Daily doseStudy groups
250 mg to 500 mg
7
500 mg to 1 g
10
1 g to 2.5 g
3
2.5 g to 5 g
3
5 g to 10 g
2
over 10 g
1

Commonly used together

7 of 32 study groups took Butyrate with something else, but nothing that 3 or more different studies gave.

32 study groups

Study
Microencapsulated sodium butyrate administered to patients with diverticulosis decreases incidence of diverticulitis--a prospective randomized study
2014 · treatment group · Adults with diverticulosis and at least one previous mild or moderate episode of diverticulitis requiring treatment; mean age 63.7 years, 17 women and 13 men among completers
300 mg1 year37
Butyrate improves handgrip strength and physical performance by reducing intestinal leak in post-menopausal women, a randomized controlled trial
2025 · butyrate · Post-menopausal women; mean age 54 ± 2.8 years
570 mg12 weeks70
Butyrate supplementation reduces sarcopenia by repairing neuromuscular junction in patients with chronic obstructive pulmonary disease
2024 · butyrate group · Patients with chronic obstructive pulmonary disease (age and sex not specified)
300 mg12 weeks64
Oral butyrate improves postural balance by repairing leaky gut in geriatric adults
2025 · butyrate group · geriatric adult men, age range 70.4 ± 2.9 years
300 mg16 weeks64
Efficacy of Microencapsulated Sodium Butyrate as Add-On Therapy in Inducing Remission in Patients with Mild-To-Moderate Ulcerative Colitis: Results From a Multi-Center, Double-Blind, Randomized, Placebo-Controlled Study
2025 · intervention group · Adults aged 18 years and older with mild-to-moderate active ulcerative colitis, receiving stable UC therapy
600 mg8 weeks54
Butyrate (short-chain fatty acid) alleviates lipopolysaccharide-binding proteins and improves physical function in knee osteoarthritis patients
2025 · butyrate group · Patients with knee osteoarthritis; age and sex not reported
300 mg12 weeks52
Colonic butyrate administration modulates fear memory but not the acute stress response in men: A randomized, triple-blind, placebo-controlled trial
2024 · butyrate group · healthy men, mean age 25.2 years
5.28 g7 days35
Gamma-hydroxybutyric acid (GHB) in the treatment of alcohol withdrawal syndrome: a randomized comparative study versus benzodiazepine
1999 · GHB group · Adults with alcohol withdrawal syndrome; mean age 41.7 years; 26 males and 4 females
50 mg/kg10 days30
Therapeutic Effects of Butyrate on Pediatric Obesity: A Randomized Clinical Trial
2022 · butyrate group · Children aged 5–17 years with obesity (BMI greater than the 95th percentile for sex and age)
20 mg/kg26 weeks27
Combined oral sodium butyrate and mesalazine treatment compared to oral mesalazine alone in ulcerative colitis: randomized, double-blind, placebo-controlled pilot study
2000 · Group A · Patients with mild to moderate ulcerative colitis
4 g6 weeks12
Nutritional Management in Stricturing Crohn's Disease: A Pilot Study
2024 · Study group: diet plus EAA and sodium butyrate supplementation · Adults with stricturing Crohn’s disease
400 mg1 year10
Calcium butyrate efficacy in pediatric irritable bowel syndrome: Randomized placebo-controlled multiomics-based clinical trial
2025 · calcium butyrate · Children aged 4–17 years with irritable bowel syndrome diagnosed according to Rome IV criteria
500 mg8 weeks26
Supplementation with short-chain fatty acids and a prebiotic improves clinical outcome in Parkinson's disease: a randomized double-blind prospective study
2025 · PA + BA + placebo · Adults aged 18–90 with a diagnosed primary Parkinsonian syndrome and moderate disease severity
2.4 g26 weeks24
Supplementation with short-chain fatty acids and a prebiotic improves clinical outcome in Parkinson's disease: a randomized double-blind prospective study
2025 · 2FL + PA + BA · Adults aged 18–90 with a diagnosed primary Parkinsonian syndrome and moderate disease severity
2.4 g26 weeks24
Effects of Oral Butyrate on Blood Pressure in Patients With Hypertension: A Randomized, Placebo-Controlled Trial
2024 · butyrate group · Dutch adults aged 40–65 with mild hypertension; men and postmenopausal women were eligible
3.9 g4 weeks12
A Patented Dietary Supplement (Hydroxy-Methyl-Butyrate, Carnosine, Magnesium, Butyrate, Lactoferrin) Is a Promising Therapeutic Target for Age-Related Sarcopenia through the Regulation of Gut Permeability: A Randomized Controlled Trial
2024 · experimental formula · Adults aged 55–85 with sarcopenia
500 mg120 days30
Exploring the Potential of Oral Butyrate Supplementation in Metabolic Dysfunction-Associated Steatotic Liver Disease: Subgroup Insights from an Interventional Study
2025 · sodium butyrate group · Adults with MASLD and cardiometabolic risk criteria
1 g12 weeks121
Exploring the Potential of Oral Butyrate Supplementation in Metabolic Dysfunction-Associated Steatotic Liver Disease: Subgroup Insights from an Interventional Study
2025 · calcium butyrate group · Adults with MASLD and cardiometabolic risk criteria
1 g12 weeks60
Microbiota changes induced by microencapsulated sodium butyrate in patients with inflammatory bowel disease
2020 · butyrose (BLM) treatment group · Adults over 18 with histologically confirmed Crohn's disease or ulcerative colitis
1.8 g60 days21
A dose-escalation phase IIa study of 2,2-dimethylbutyrate (HQK-1001), an oral fetal globin inducer, in sickle cell disease
2013 · 50 mg/kg HQK-1001 · People with hemoglobin SS or S/β(0) thalassemia
50 mg/kg26 weeks19
A dose-escalation phase IIa study of 2,2-dimethylbutyrate (HQK-1001), an oral fetal globin inducer, in sickle cell disease
2013 · 40 mg/kg HQK-1001 · People with hemoglobin SS or S/β(0) thalassemia
40 mg/kg26 weeks18
Effects of short-chain fatty acid-butyrate supplementation on expression of circadian-clock genes, sleep quality, and inflammation in patients with active ulcerative colitis: a double-blind randomized controlled trial
2024 · sodium-butyrate group · Adults aged 18–60 with mild to moderate active ulcerative colitis
600 mg12 weeks18
A Sustained-Release Butyrate Tablet Suppresses Ex Vivo T Helper Cell Activation of Osteoarthritis Patients in a Double-Blind Placebo-Controlled Randomized Trial
2024 · sustained-release butyrate tablet group · Adults aged 50–74 years with hand osteoarthritis
600 mg4 weeks16
A dose-escalation phase IIa study of 2,2-dimethylbutyrate (HQK-1001), an oral fetal globin inducer, in sickle cell disease
2013 · 30 mg/kg HQK-1001 · People with hemoglobin SS or S/β(0) thalassemia
30 mg/kg26 weeks15
The 2-monoacylglycerol moiety of dietary fat appears to be responsible for the fat-induced release of GLP-1 in humans
2015 · 200 g carrots + 6.53 g tributyrin · Healthy white men, mean age 24 years, mean BMI 22
6.53 g1 day12
Infusion of donor feces affects the gut-brain axis in humans with metabolic syndrome
2020 · butyrate group · Men or post-menopausal women aged 50–70 years with metabolic syndrome
4 g4 weeks12
Butyrate esterified to starch is released in the human gastrointestinal tract
2011 · HAMSB20 · 16 volunteers; age, sex, and health condition not specified
31.8 mmol2 weeks—
Butyrate esterified to starch is released in the human gastrointestinal tract
2011 · HAMSB40 · 16 volunteers; age, sex, and health condition not specified
40 g2 weeks—
Effects of oral butyrate and inulin supplementation on inflammation-induced pyroptosis pathway in type 2 diabetes: A randomized, double-blind, placebo-controlled trial
2020 · group A · People with type 2 diabetes; age and sex not reported
600 mg45 days—
Expression of PGC-1α, PPAR-α and UCP1 genes, metabolic and anthropometric factors in response to sodium butyrate supplementation in patients with obesity: a triple-blind, randomized placebo-controlled clinical trial
2025 · NaB group · People with obesity
600 mg8 weeks—
Effect of Supplementation of a Butyrate-Based Formula in Individuals with Liver Steatosis and Metabolic Syndrome: A Randomized Double-Blind Placebo-Controlled Clinical Trial
2024 · Active treatment · Adults with ultrasound-diagnosed liver steatosis and metabolic syndrome
1 g12 weeks25
Effects of oral butyrate and inulin supplementation on inflammation-induced pyroptosis pathway in type 2 diabetes: A randomized, double-blind, placebo-controlled trial
2020 · group C · People with type 2 diabetes; age and sex not reported
600 mg45 days—